Get the Stockscreener App
25.82
8.53%
2.03
Monopar Therapeutics Inc Stock (MNPR) Forecast
The Monopar Therapeutics Inc (MNPR) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $15.29, representing a -40.78% decrease from the current price of $25.82. The highest analyst price target is $15.11, and the lowest is $15.47.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month MNPR Price Target
Average 13.95
(-45.98% Downside)
Is Monopar Therapeutics Inc (MNPR) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 57.89 | Neutral |
| STOCH(9,6) | 69.44 | Neutral |
| STOCHRSI(14) | 17.58 | Buy |
| MACD(12,26) | 2.6345 | Sell |
| ADX(14) | 53.10 | Buy |
| William %R | -52.99 | Neutral |
| CCI(14) | 43.00 | Neutral |
Buy: 2
Sell: 1
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
25.59
Buy
|
25.58
Buy
|
| MA20 |
23.52
Buy
|
23.69
Buy
|
| MA50 |
17.85
Buy
|
18.60
Buy
|
| MA100 |
10.50
Buy
|
13.25
Buy
|
| MA200 |
5.606
Buy
|
8.3884
Buy
|
Buy: 10
Sell: 0
Neutral: 0
Summary: Buy
According to our latest analysis, MNPR could be considered a Strong Buy, with 17 technical analysis indicators signaling 12 Buy signals, 1 signaling Sell signals and 4 Neutral signals. This might be a good time to open fresh positions on MNPR, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 57.89 indicates that MNPR is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 69.44 indicates that MNPR is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 17.58 indicates that MNPR is oversold. This suggests that MNPR price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 53.1 suggests an extremely strong trend in the market. Such high values are relatively rare and indicate a very robust directional movement.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 43 indicates that MNPR is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term MNPR price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Monopar Therapeutics Inc financial reports and earnings history, Monopar Therapeutics Inc (MNPR) stock could reach $38.76 by 2030, $83.51 by 2040 and $126.21 by 2050. See the projected annual prices until 2050 of the Monopar Therapeutics Inc stock below:
- Monopar Therapeutics Inc (MNPR) is expected to reach an average price of $61.30 in 2035, with a high prediction of $61.14 and a low estimate of $61.26. This indicates an $137.41% rise from the last recorded price of $25.82.
- Monopar Therapeutics Inc (MNPR) stock is projected to chart a bullish course in 2040, with an average price target of $82.85, representing an $220.88% surge from its current level. The forecast ranges from a conservative $83.25 to a sky-high $83.51.
- Our analysts predict Monopar Therapeutics Inc (MNPR) to jump 303.66% by 2045, soaring from $104.51 to an average price of $104.23, potentially reaching $105.25. While $104.51 is the low estimate, the potential upside is significant.
- Monopar Therapeutics Inc (MNPR) stock is expected to climb by 2050, reaching an average of $125.10, a $384.51% jump from its current level. However, a wide range of estimates exists, with high and low targets of $126.21 and $125.25, respectively, highlighting the market's uncertainty.
Monopar Therapeutics Inc Stock (MNPR) Year by Year Forecast
Monopar Therapeutics Inc Stock (MNPR) Price Forecast for 2025
Monopar Therapeutics Inc Stock (MNPR) is expected to reach an average price of $13.95 in 2025, with a high prediction of $16.55 and a low estimate of $11.35. This indicates an -45.98% fall from the last recorded price of $25.82.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $16.74 | $15.47 | $15.11 | -35.18% |
| February, 2025 | $16.94 | $16.70 | $16.53 | -34.39% |
| March, 2025 | $16.43 | $16.74 | $16.49 | -36.37% |
| April, 2025 | $16.85 | $16.58 | $16.35 | -34.75% |
| May, 2025 | $15.91 | $16.08 | $16.55 | -38.38% |
| June, 2025 | $14.74 | $15.33 | $15.76 | -42.90% |
| July, 2025 | $13.00 | $13.68 | $13.33 | -49.66% |
| August, 2025 | $11.10 | $11.35 | $11.24 | -57.02% |
| September, 2025 | $12.15 | $12.20 | $11.75 | -52.94% |
| October, 2025 | $13.39 | $12.75 | $13.05 | -48.12% |
| November, 2025 | $13.20 | $12.89 | $12.86 | -48.89% |
| December, 2025 | $12.00 | $12.08 | $12.45 | -53.52% |
Monopar Therapeutics Inc Stock (MNPR) Price Forecast for 2026
The predicted value for Monopar Therapeutics Inc (MNPR) in 2026 is set at an average of $11.06. Estimates vary from a peak of $11.74 to a trough of $10.39, indicating an -57.16% surge from the present price of $25.82.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $11.69 | $11.79 | $11.52 | -54.71% |
| February, 2026 | $11.89 | $12.02 | $11.58 | -53.96% |
| March, 2026 | $11.45 | $11.78 | $11.74 | -55.66% |
| April, 2026 | $11.25 | $11.37 | $11.29 | -56.42% |
| May, 2026 | $11.15 | $11.18 | $11.17 | -56.83% |
| June, 2026 | $10.62 | $10.68 | $10.42 | -58.87% |
| July, 2026 | $10.92 | $10.75 | $10.83 | -57.70% |
| August, 2026 | $11.48 | $11.41 | $11.13 | -55.56% |
| September, 2026 | $10.99 | $11.27 | $11.36 | -57.44% |
| October, 2026 | $10.32 | $10.39 | $10.51 | -60.02% |
| November, 2026 | $10.59 | $10.64 | $10.42 | -58.97% |
| December, 2026 | $10.37 | $10.39 | $10.42 | -59.84% |
Monopar Therapeutics Inc Stock (MNPR) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Monopar Therapeutics Inc (MNPR) is $7.3955, with a high forecast of $10.26 and a low forecast of $4.5313. This indicates an -71.36% decrease from the last price of $25.82.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $10.00 | $10.32 | $10.26 | -61.27% |
| February, 2027 | $9.5539 | $9.9638 | $9.8518 | -63.00% |
| March, 2027 | $9.1075 | $9.1875 | $9.4146 | -64.73% |
| April, 2027 | $9.0103 | $9.1582 | $8.9797 | -65.10% |
| May, 2027 | $8.7633 | $8.8632 | $8.9118 | -66.06% |
| June, 2027 | $8.3567 | $8.5967 | $8.6952 | -67.63% |
| July, 2027 | $7.2096 | $7.7096 | $8.0874 | -72.08% |
| August, 2027 | $6.6924 | $6.701 | $6.4239 | -74.08% |
| September, 2027 | $6.3151 | $6.5189 | $6.5731 | -75.54% |
| October, 2027 | $5.4788 | $5.6688 | $6.2667 | -78.78% |
| November, 2027 | $4.2917 | $4.5313 | $4.6595 | -83.38% |
| December, 2027 | $4.7581 | $4.6431 | $4.5046 | -81.57% |
Monopar Therapeutics Inc Stock (MNPR) Price Forecast for 2028
In 2028, Monopar Therapeutics Inc (MNPR) is projected to reach an average price of $3.8128, with a high projection of $5.6381 and a low estimate of $1.9876. This indicates an -85.23% fall from the last price of $25.82.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $5.8281 | $4.7266 | $5.6381 | -77.43% |
| February, 2028 | $5.6995 | $5.7095 | $5.6288 | -77.93% |
| March, 2028 | $5.2044 | $5.3341 | $5.5616 | -79.84% |
| April, 2028 | $4.9423 | $4.9923 | $5.0552 | -80.86% |
| May, 2028 | $4.5599 | $4.5897 | $4.8401 | -82.34% |
| June, 2028 | $4.2437 | $4.2934 | $4.4338 | -83.56% |
| July, 2028 | $3.9012 | $3.9398 | $4.1145 | -84.89% |
| August, 2028 | $3.554 | $3.583 | $3.7693 | -86.24% |
| September, 2028 | $3.2443 | $3.2624 | $3.4209 | -87.43% |
| October, 2028 | $2.8858 | $2.9358 | $3.1728 | -88.82% |
| November, 2028 | $2.295 | $2.3883 | $2.6766 | -91.11% |
| December, 2028 | $1.9868 | $1.9876 | $2.1401 | -92.31% |
Monopar Therapeutics Inc Stock (MNPR) Price Forecast for 2029
The 2029 price forecast for Monopar Therapeutics Inc Stock (MNPR) is $21.11 on average, with a high prediction of $42.12 and a low estimate of $0.0979. This represents an -18.25% decrease from the previous price of $25.82.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $0.9958 | $1.1236 | $1.843 | -96.14% |
| February, 2029 | $0.7391 | $0.7987 | $0.7765 | -97.14% |
| March, 2029 | $0.3914 | $0.4099 | $0.5294 | -98.48% |
| April, 2029 | $25.70 | $0.0979 | $4.70 | -0.46% |
| May, 2029 | $34.40 | $34.66 | $33.63 | +33.22% |
| June, 2029 | $38.51 | $35.11 | $34.82 | +49.13% |
| July, 2029 | $43.71 | $41.04 | $41.12 | +69.28% |
| August, 2029 | $42.32 | $42.60 | $42.12 | +63.90% |
| September, 2029 | $41.18 | $41.52 | $41.00 | +59.49% |
| October, 2029 | $39.74 | $39.74 | $40.13 | +53.91% |
| November, 2029 | $39.08 | $39.14 | $38.39 | +51.37% |
| December, 2029 | $38.05 | $38.45 | $38.52 | +47.37% |
Monopar Therapeutics Inc Stock (MNPR) Price Forecast for 2030
Monopar Therapeutics Inc Stock (MNPR) is expected to reach an average price of $34.21 in 2030, with a high forecast of $38.76 and a low forecast of $29.67. This signifies an +32.51% surge from the last price of $25.82.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $39.02 | $38.29 | $38.76 | +51.11% |
| February, 2030 | $38.72 | $38.72 | $38.76 | +49.97% |
| March, 2030 | $37.92 | $38.27 | $38.08 | +46.86% |
| April, 2030 | $37.98 | $37.97 | $37.73 | +47.11% |
| May, 2030 | $36.54 | $36.81 | $37.03 | +41.52% |
| June, 2030 | $34.47 | $34.55 | $34.78 | +33.49% |
| July, 2030 | $31.69 | $32.45 | $33.53 | +22.75% |
| August, 2030 | $32.57 | $30.95 | $31.15 | +26.14% |
| September, 2030 | $31.81 | $31.40 | $30.94 | +23.18% |
| October, 2030 | $31.00 | $31.39 | $31.76 | +20.07% |
| November, 2030 | $30.51 | $31.09 | $31.17 | +18.16% |
| December, 2030 | $29.06 | $29.67 | $29.82 | +12.56% |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):